In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
Shares of Pfizer (NYSE: PFE) have been stuck in the mud since December 2022, with its shares down more than 45% over that ...
Pfizer Inc. CEO Albert Bourla is set to meet with activist investor Starboard Value amid growing pressure to revitalize the ...
Pfizer’s 2023 U.S.-booked air volume increased $17.4 million from the prior year. Of that volume, 55 percent was for internal travel and 41 percent was for domestic travel. Following a full return ...
Looking at Pfizer's recent performance in business turnaround, I think the recovery in PFE stock should continue in the medium term - the 10% total return since June 2024 may be just the beginning ...
Pfizer will receive around 2.66 billion pounds ($3.56 billion) in aggregate from Haleon from an offering and a share buyback. Goldman Sachs International said Tuesday that the pharmaceutical ...
Pfizer is a global pharmaceutical giant with an impressive portfolio of over 350 marketed medicines, 113 experimental candidates in clinical trials, and a presence in more than 200 countries.
Sept. 14 (UPI) --A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drugmaker Pfizer announced Saturday. The ...
Pfizer's RSI is trending upward, bouncing from the 50 support level, signaling potential stock strength and accumulation. Pfizer's KP.2-adapted COVID-19 vaccine received FDA approval, positioning ...
Pfizer Inc (NYSE:PFE) shares are on the move Monday after activist Starboard Value acquired a $1 billion stake in the pharmaceutical giant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback